Therefore, BRAF V600E mutation was significantly associated with age less than 54 years old among ameloblastoma patients, as shown in the pooled analysis (OR = 3.42; 95% CI = 1.94–6.04; p < 0.0001) based on FEM, as the heterogeneity was not significant (p = 0.11; I2 = 38%). The gene discussed is BRAF; the disease is ameloblastoma.